Esperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016

Esperion Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016.

Analysis

  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -14.04 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • ESPR-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were down this period to 207.18 million compared to 224.78 million in the same period last year.
  • With debt at a relatively low 18.47% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 8.79%), and relatively tight interest coverage level of -120.23x, ESPR-US would have a hard time raising much additional debt. Thus, the company is classified as having Limited Flexibility when it comes to raising more debt.
  • Of the 8 chosen peers for the company, only 6 of the stocks have an outstanding debt balance. Companies with no debt include RARE-US and BIOD-US.
  • Net income of -14.04 million this period compared to a net income of -14.59 million last period. This is a growth of 3.77% over the previous period. In comparison, the peer group grew at -7.90%

Access our Ratings and Scores for Esperion Therapeutics, Inc.

Earnings Growth YOY %
Cash & ST Investments

Access our Ratings and Scores for Esperion Therapeutics, Inc.

Company Profile

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. The company operates through one segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. Esperion Therapeutics was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of ESPR-US.